Overcoming Barriers to Non-invasive Delivery of Macromolecules
Sponsored by: Catalent Pharma Solutions
Date: 7 December
Time: 10AM New York/3PM London
Parallel screening approaches for non-invasive delivery of macromolecules
Today, a majority of biological therapies are delivered via traditional but invasive injectable formats. This often results in poor patient compliance and is not the most suitable route for chronic treatments. Non-invasive delivery of macromolecules is a dynamic research field. Several tactics have been developed to overcome biological barriers, however, they are limited by focusing on a single delivery technology and siloed approach.
In this webinar, the Non-Invasive Macromolecule Delivery Consortium experts will provide insights on physiological and formulation challenges in delivering macromolecules and strategies on overcoming these challenges. It will feature a new and integrated solution designed to rapidly screen biomolecules potential for non-invasive delivery route, assess formulation strategies in parallel, and deliver animal study material in as little as 3 weeks at a minimal price.
Ronak Savla, Pharm.D., Ph.D.,
Scientific Affairs Manager, Catalent Pharma Solutions
Ronak Savla is the Scientific Affairs Manager at Catalent Pharma Solutions and the Catalent Applied Drug Delivery Institute. He earned his Pharm.D. and Ph.D. from Rutgers University. His current research interests include the application of in silico models and simulations to aid in drug formulation design, integration of novel formulation technologies into the industry, and patient centric drug design. Dr. Savla is an author or co-author on over 35 publications including peer reviewed papers, articles, conference proceedings, and posters.
David J Brayden, Ph.D.,
Professor of Drug Delivery, University College Dublin
Dr. David Brayden is Full Professor of Advanced Drug Delivery at the School of Veterinary Medicine and a Fellow of the UCD Conway Institute. He received his Ph.D. in Pharmacology at the University of Cambridge and did a post-doctoral research fellowship at Stanford University. Afterwards, he set up Elan Corporation's pharmacology laboratory in Dublin, where he became a senior scientist and project manager. In 2001, he joined UCD as a lecturer in veterinary pharmacology and rose to the rank of Full Professor of Advanced Drug Delivery. His major research interests are in oral peptide delivery. He is the author or co-author of more than 200 research publications and patents. In 2012, he was inducted into the College of Fellows of the Controlled Release Society. Professor Brayden serves on the Editorial Advisory Boards of several peer review journals. Professor Brayden works as an independent consultant for drug delivery companies.
Key Learning Objectives
- Learn how different oral delivery technologies overcome biologic barriers for macromolecules
- Understand how parallel screening can expedite the oral development for macromolecules
- Understand what molecule characteristics make a molecule good fit for oral delivery route
- Formulation Scientist
- Head of Development
- Head of Pharmaceutical Technology
- Director Formulation
- Director CMC
- VP Pharmaceutical R&D
- Director Formulation Development
- Head of Product Development